The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

America needs a new blueprint for the National Cancer Program

First step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Source: Yale Cancer Center

Recently, a friend lent me a copy of a decades-old report, and by old, I mean a classic. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Robert A. Winn, MD
Director and Lipman Chair in Oncology, VCU Massey Comprehensive Cancer Center, Senior associate dean for cancer innovation, VCU School of Medicine, Professor, Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University; Incoming director, Fox Chase Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.
By Sara Willa Ernst
Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.
By Richard M. Goldberg
Byline
Robert A. Winn, MD
Director and Lipman Chair in Oncology, VCU Massey Comprehensive Cancer Center, Senior associate dean for cancer innovation, VCU School of Medicine, Professor, Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University; Incoming director, Fox Chase Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account